Top-down therapy: Is the evidence strong enough?

Digestive Diseases

Volumn 27, Issue 3, 2009, Pages 306-311

  Domènech, Eugeni ^a   Mañosa, Míriam ^b   Cabré, Eduard ^b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b NONE

Author keywords

Anti TNF; Biologicals; Crohn's disease; Immunomodulators; Inflammatory bowel disease; Mucosal healing; Top down therapy

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PLACEBO; PREDNISONE; STEROID;

CONFERENCE PAPER; CROHN DISEASE; DISEASE DURATION; DRUG EFFICACY; HUMAN; INTESTINE RESECTION; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE;

CROHN DISEASE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INTESTINAL MUCOSA; PURINES; TIME FACTORS; WOUND HEALING;

EID: 70349896201     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000228565     Document Type: Conference Paper

References (27)

1. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J: Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001; 49: 777-782. (Pubitemid 33096034)
2. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, Gendre JP: Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-250. (Pubitemid 34784976)
3. Veloso FT, Ferreira JT, Barros L, Almeida S: Clinical outcome of Crohn's disease: analysis according to the Vienna classification and clinical activity. Inflamm Bowel Dis 2001; 7: 306-313. (Pubitemid 33069342)
4. Romberg-Camps MJ, Dagnelie PC, Kester AD, Hesselink-van de Kruijs MA, Cilissen M, Engels LG, Van Deursen C, Hameeteman WH, Wolters FL, Russel MG, Stockbrügger RW: Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol 2009; 104: 371-383.
5. Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J: The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006; 24: 319-330. (Pubitemid 43972900)
6. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ: The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-260. (Pubitemid 32729372)
7. Hanauer S, Sandborn WJ, Persson A, Persson T: Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther 2005; 21: 363-371. (Pubitemid 40320545)
8. Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG: Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000; 95: 3189-3194. (Pubitemid 30826295)
9. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F: A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895-902. (Pubitemid 30777909)
10. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R: A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37: 674-678.
11. Lémann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Delchier JC, Laharie D, Moreau J, Cadiot G, Picon L, Bourreille A, Sobahni I, Colombel JF; Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID): Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006; 130: 1054-1061.
12. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenkühn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club: Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-667.
13. Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R, REACH Study Group: Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007; 132: 863-873. (Pubitemid 46454266)
14. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Hanauer SB: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-413. (Pubitemid 38182297)
15. Kugathasan S, Saubermann LJ, Smith L, Kou D, Itoh J, Binion DG, Levine AD, Blumberg RS, Fiocchi C: Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut 2007; 56: 1696-1705. (Pubitemid 350206296)
16. Jaspers GJ, Verkade HJ, Escher JC, de Ridder L, Taminiau JA, Rings EH: Azathioprine maintains first remission in newly diagnosed pediatric Crohn's disease. Inflamm Bowel Dis 2006; 12: 831-836.
17. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP: Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54: 237-241. (Pubitemid 40139240)
18. Vernier-Massouille G, Balde M, Salleron J, Turck D, Dupas JL, Mouterde O, Merle V, Salomez JL, Branche J, Marti R, Lerebours E, Cortot A, Gower-Rousseau C, Colombel JF: Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology 2008; 135: 1106-1113.
19. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M: Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99: 956-963. (Pubitemid 20338451)
20. Landi B, Anh TN, Cortot A, Soule JC, Rene E, Gendre JP, Bories P, See A, Metman EH, Florent C; and The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives: Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. Gastroenterology 1992; 102: 1647-1653.
21. Fell JM, Paintin M, Arnaud-Battandier F, Beattie RM, Hollis A, Kitching P, Donnet- Hughes A, MacDonald TT, Walker-Smith JA: Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther 2000; 14: 281-289. (Pubitemid 30145315)
22. Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Patel K, Wolf DC, Safdi M, Colombel JF, Lashner B, Hanauer SB: Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006; 63: 433-442. (Pubitemid 43261469)
23. D'Haens G, Geboes K, Rutgeerts P: Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc 1999; 50: 667-671. (Pubitemid 29518050)
24. Baert P, Moortgat L, Van Assche GA, Caenepeel P, Vergauwe PL, De Vos M, Stokkers PC, Hommes DW, Vermeire S, Rutgeerts PJ, Feagan B, D'Hanes G: Mucosal healing predicts sustained clinical remission in early Crohn's disease. Gastroenterology 2008; 134(suppl 1):A-640.
25. Shergill AK, Terdiman JP: Controversies in the treatment of Crohn's disease: the case for an accelerated step-up treatment approach. World J Gastroenterol 2008; 14: 2670-2677.
26. Armuzzi A, De Pascalis B, Fedeli P, De Vincentis F, Gasbarrini A: Infliximab in Crohn's disease: early and long-term treatment. Dig Liver Dis 2008; 40(suppl 2):S271-S279. (Pubitemid 351878071)
27. Cullen G, O'Toole A, Keegan D, Sheahan K, Hyland JM, O'Donoghue DP: Long-term clinical results of ileocecal resection for Crohn's disease. Inflamm Bowel Dis 2007; 13: 1369-1373. (Pubitemid 350206847)